Gisslen M - Search Results

1

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW. Spudich S, et al. Among authors: gisslen m. J Infect Dis. 2011 Sep 1;204(5):753-60. doi: 10.1093/infdis/jir387. J Infect Dis. 2011. PMID: 21844301 Free PMC article.

2

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Abdulle S, et al. Among authors: gisslen m. AIDS. 2002 Nov 8;16(16):2145-9. doi: 10.1097/00002030-200211080-00006. AIDS. 2002. PMID: 12409735

3

The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.

Cinque P, Nebuloni M, Santovito ML, Price RW, Gisslen M, Hagberg L, Bestetti A, Vago G, Lazzarin A, Blasi F, Sidenius N. Cinque P, et al. Among authors: gisslen m. Ann Neurol. 2004 May;55(5):687-94. doi: 10.1002/ana.20076. Ann Neurol. 2004. PMID: 15122709

4

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.

Arvidson N, Gisslén M, Albert J, Brandin E, Svennerholm B, Fuchs D, Hagberg L. Arvidson N, et al. Among authors: gisslen m. AIDS Res Hum Retroviruses. 2004 Jul;20(7):711-5. doi: 10.1089/0889222041524625. AIDS Res Hum Retroviruses. 2004. PMID: 15307916

5

Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.

Sidenius N, Nebuloni M, Sala S, Zerbi P, Price RW, Gisslen M, Hagberg L, Vago L, Lazzarin A, Blasi F, Cinque P. Sidenius N, et al. Among authors: gisslen m. J Neuroimmunol. 2004 Dec;157(1-2):133-9. doi: 10.1016/j.jneuroim.2004.08.038. J Neuroimmunol. 2004. PMID: 15579290

6

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. Scand J Infect Dis. 2004;36(11-12):823-8. doi: 10.1080/00365540410025320. Scand J Infect Dis. 2004. PMID: 15764168 Clinical Trial.

7

Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.

Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, Price RW. Cinque P, et al. Among authors: gisslen m. J Neuroimmunol. 2005 Nov;168(1-2):154-63. doi: 10.1016/j.jneuroim.2005.07.002. Epub 2005 Aug 8. J Neuroimmunol. 2005. PMID: 16091292

8

Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection.

Gisslén M, Rosengren L, Hagberg L, Deeks SG, Price RW. Gisslén M, et al. AIDS Res Ther. 2005 Aug 18;2:6. doi: 10.1186/1742-6405-2-6. AIDS Res Ther. 2005. PMID: 16109178 Free PMC article.

9

Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, Gisslén M. Mellgren A, et al. Among authors: gisslen m. Antivir Ther. 2005;10(6):701-7. Antivir Ther. 2005. PMID: 16218168 Clinical Trial.

10

Temporarily controlled HIV-1 replication after intravenous immunoglobulin treatment of Guillain-Barré syndrome.

Gisslén M, Fredman P, Fuchs D, Lekman A, Rosengren L. Gisslén M, et al. Scand J Infect Dis. 2005;37(11-12):877-81. doi: 10.1080/00365540500277227. Scand J Infect Dis. 2005. PMID: 16308224

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters